Preoperative Low Prealbumin Is Associated With Recurrence in Patients With Stage II/III Gastric Cancer After Laparoscopic D2 Gastrectomy

被引:7
|
作者
Gao, Chun [1 ]
Zeng, Ci Dian Dan [1 ]
Tong, Yi Xin [1 ]
Zhu, Li [1 ]
Zhang, Sheng [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
关键词
gastric cancer; recurrence; risk factor; prealbumin; recurrence-free survival; cancer; PROGNOSTIC NUTRITIONAL INDEX; ADJUVANT CHEMOTHERAPY; CURATIVE RESECTION; METASTASES; INDICATOR; SURVIVAL; COMPLICATIONS; CARCINOMA; JAPANESE; SURGERY;
D O I
10.3389/fsurg.2022.819514
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundPostoperative recurrence is associated with poor prognosis in patients with gastric cancer. This study aimed to explore predictive factors contributing to recurrence in patients with stage II/III gastric cancer after laparoscopic D2 gastrectomy. MethodsThis retrospective study was conducted at a single tertiary referral hospital. Patients diagnosed with gastric cancer who met the inclusion criteria were included in the study. The clinicopathological characteristics of the patients were collected. The patients were divided into recurrence and non-recurrence groups. The predictive factors were investigated using univariate and multivariate analyses. ResultsIn total, 462 patients were included. The incidence of recurrence was 26.4% (122/462) in all patients. The most common recurrence pattern was haematogenous recurrence. In the multivariate analysis, the independent predictive factors for recurrence were serum prealbumin level (p < 0.001), prognostic nutritional index (p = 0.001), carbohydrate antigen 19-9 (CA19-9) (p < 0.001), number of lymph node metastases (p < 0.001), signet-ring cell carcinoma (p = 0.001), tumor deposit (p = 0.001), and no/incomplete adjuvant chemotherapy (p < 0.001). ConclusionsOur findings revealed that nutritional status was an independent predictive factor for recurrence in patients with gastric cancer after D2 gastrectomy. We suggest that patients with risk factors for recurrence receive both nutritional support and intense surveillance.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer
    Yu, Yuanyuan
    Zhang, Zicheng
    Meng, Qianhao
    Wang, Ke
    Li, Qingwei
    Ma, Yue
    Yao, Yuanfei
    Sun, Jie
    Wang, Guangyu
    JOURNAL OF GASTRIC CANCER, 2022, 22 (02) : 107 - 119
  • [32] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
    Kohei Shitara
    Keisho Chin
    Takaki Yoshikawa
    Hitoshi Katai
    Masanori Terashima
    Seiji Ito
    Motohiro Hirao
    Kazuhiro Yoshida
    Eiji Oki
    Mitsuru Sasako
    Yasunori Emi
    Toshimasa Tsujinaka
    Gastric Cancer, 2017, 20 : 175 - 181
  • [33] The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data
    Xu, Bin-bin
    Lu, Jun
    Zheng, Zhi-fang
    Xie, Jian-wei
    Wang, Jia-bin
    Lin, Jian-xian
    Chen, Qi-yue
    Cao, Long-long
    Lin, Mi
    Tu, Ru-hong
    Huang, Ze-ning
    Lin, Ju-li
    Zheng, Chao-hui
    Huang, Chang-ming
    Li, Ping
    GASTRIC CANCER, 2019, 22 (05) : 1016 - 1028
  • [34] Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy
    Lee, Juhan
    Kim, Yoo-Min
    Woo, Yanghee
    Obama, Kazutaka
    Noh, Sung Hoon
    Hyung, Woo Jin
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2015, 29 (11): : 3251 - 3260
  • [35] Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study
    Li, Qiwen
    Li, Guichao
    Palmer, Joshua D.
    Zhang, Zhen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (04): : 375 - 380
  • [36] Impact of preoperative prealbumin levels on long-term prognosis in patients with gastric cancer after gastrectomy: a retrospective cohort study
    Matsui, Ryota
    Ida, Satoshi
    Ri, Motonari
    Makuuchi, Rie
    Hayami, Masaru
    Kumagai, Koshi
    Ohashi, Manabu
    Sano, Takeshi
    Nunobe, Souya
    GASTRIC CANCER, 2024, 27 (03) : 611 - 621
  • [37] Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma
    He, Ming-Ming
    Zhang, Dong-Sheng
    Wang, Feng
    Wang, Zhi-Qiang
    Luo, Hui-Yan
    Ren, Chao
    Jin, Ying
    Chen, Dong-Liang
    Xu, Rui-Hua
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (01) : 264 - 273
  • [38] The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation
    Chiu, Chang-Fang
    Yang, Horng-Ren
    Yang, Mei-Due
    Jeng, Long-Bin
    Sargeant, Aaron M.
    Yeh, Su-Peng
    Bai, Li-Yuan
    SPRINGERPLUS, 2016, 5
  • [39] Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration
    Chang, Jee Suk
    Kim, Kyung Hwan
    Keum, Ki Chang
    Noh, Sung Hoon
    Lim, Joon Seok
    Kim, Hyo Song
    Rha, Sun Young
    Lee, Yong Chan
    Hyung, Woo Jin
    Koom, Woong Sub
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 114 (07) : 859 - 864
  • [40] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
    Fujitani, Kazumasa
    Tamura, Shigeyuki
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    GASTRIC CANCER, 2014, 17 (02) : 348 - 353